J Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients ...